Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 2-week, Phase 1b, Randomized, Double-Blind, Placebo- Controlled, Multi-Dose, Dose-Escalating Study With PF-03882845 And One Dose Of Spironolactone To Evaluate Safety, Tolerability, Pharmacokinetics And Pharmacodynamics In Subjects With Type 2 Diabetes Mellitus And Albuminuria

NCT01488877 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01488877
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01488877 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 2-week, Phase 1b, Randomized, Double-Blind, Placebo- Controlled, Multi-Dose, Dose-Escalating Study With PF-03882845 And One Dose Of Spironolactone To Evaluate Safety, Tolerability, Pharmacokinetics And Pharmacodynamics In Subjects With Type 2 Diabetes Mellitus And Albuminuria
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Terminated
Start date
January 31, 2012
Completion date
July 31, 2012
Enrollment
6 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetic nephropathy